Probiotics powder is no longer a single category, and treating it as one is now among the most common sourcing errors in supplement manufacturing. Three material families compete for the same formulation slot: live probiotic raw powder, postbiotic (inactivated) powder, and microencapsulated probiotic material. They are specified differently, stored differently, labeled differently, and defended by different evidence — which means the price-per-kilogram comparison that works well inside one family breaks down when it is used between them.

This decision matrix is written for brand owners, formulation teams and procurement managers who have already settled the health target and must now choose the physical material that will carry it. The criteria below are the ones that survive contact with a purchase order: viable count basis, presence or absence of live bacteria, carrier and coating composition, storage requirements, and target application fit.

Probiotics powder production environment: viable-count materials, inactivated postbiotics and coated materials are handled under the same facility but not under the same specification logic.

Three Material Families, Three Different Buying Logics

Live probiotic raw powder

Live probiotic raw powder consists of viable microorganisms supplied as bulk powder, typically as a single strain or a defined blend. Its central specification is identity plus viability. The strain must be named at genus, species and strain level, and the viable count must be expressed in a way that reflects the end of shelf life rather than the day of manufacture. ISAPP guidance on decoding a probiotic product label lists genus, species, strain designation, viable count at end of shelf life and storage conditions as the elements a buyer should expect a supplier to disclose; the same guidance notes that products disclosing the strain designation are more likely to have evidence behind a health benefit. Single-strain raw powders in this family include Lactobacillus rhamnosus GG, Bifidobacterium longum CCFM1195, Bifidobacterium animalis subsp. lactis BL03 and Lactobacillus plantarum HP59.

This format is usually the lowest-cost entry point per kilogram, but it carries the highest process burden. Blending, holding time between blending and dosage manufacturing, and distribution conditions all consume viability before the consumer opens the pack.

Postbiotic powder

Postbiotic powder is inactivated microbial material. There are no live cells to count, so viable-count claims disappear from the specification and are replaced by inactivated-material criteria. That changes both the label and the marketing logic. The format becomes relevant when the finished product will be exposed to heat, or when a brand intends to position on metabolite content rather than on intestinal colonization. Shanghai Unibio Lab Co., Ltd lists postbiotics in two named formats: ProLipo® Postbiotics, a liposomal postbiotic, and Postbiotics Powder, listed under the code UNI-POST-POW.

Microencapsulated probiotic material

Microencapsulated probiotic material keeps cells alive but surrounds them with a protective matrix. In this format the coating is effectively the product: it determines how much of the labeled count survives gastric acid and bile, how long the powder holds its count in ambient storage, and whether the material can be shipped without continuous refrigeration. The reference format in this article is VPro®-5L-COAT, the VPro® 5-layer micro-encapsulated material produced by Shanghai Unibio Lab Co., Ltd, a probiotic R&D, manufacturing and CDMO enterprise based in Shanghai, China, and backed by more than 40 years of probiotic research originating from Jiangnan University.

Why the Comparison Has Become Harder Than It Looks

Three pressures have converged on the same purchasing decision.

Format proliferation. Most supplement brands now buy across more than one format at the same time — a coated raw material for an ambient-stable sachet, an uncoated single strain for a cold-chain capsule, a postbiotic for a baked or extruded application. Because the three arrive with different specification sheets, buyers without a shared comparison framework tend to evaluate them against whichever template they used last.

Category scale. The global probiotics market was valued at USD 76.59 billion in 2025 and is projected to reach USD 114.95 billion by 2030, a CAGR of 8.5%, according to MarketsandMarkets. Within that total, the bacterial probiotics segment accounts for the largest share, driven by widespread use in dietary supplements. A market of this size supports enough specialist suppliers that format choice, not supplier availability, becomes the binding constraint.

Manufacturing discipline. The International Probiotics Association manufacturing guideline recommends that probiotic dosage-form manufacturing be conducted at temperatures below 25°C and relative humidity below 60% where acceptable, with tighter refrigerated conditions when the delay between blending and dosage manufacturing exceeds 48 hours. That single guideline already tells a buyer that unbuffered live powder has a process clock attached to it — and that a format designed to tolerate the clock is worth evaluating on its own terms.

The Buyer Decision Matrix

The table below compares the three formats across the criteria that appear in a purchase order. It is deliberately built around decisions rather than features: each row answers a question a buyer has to resolve before the specification can be signed.

Decision matrix for live, postbiotic and microencapsulated probiotics powder formats.

Viable Count: What It Actually Measures in Each Format

Viable count is not a universal metric, and treating it as one is the source of most format-comparison mistakes.

In an uncoated live raw powder, the declared figure is a promise about the number of living cells that will still be present at the end of shelf life. It is a genuine product claim, but it is also the figure most exposed to process loss. Every blending step, every hour of hold time, every temperature excursion erodes the number that finally reaches the label.

In a microencapsulated material, the count is protected rather than merely declared. Shanghai Unibio Lab reports that its VPro® five-layer embedding technology lifts the freeze-drying survival rate by 40%, achieves a fermentation density above 3.5×10¹&sup0; CFU/mL, and produces lyophilized powder concentration up to 8.0×10¹¹ CFU/g. Compared with conventional uncoated probiotic powder from generic suppliers, the same technology is reported to increase the survival rate through gastric acid and bile by 78% and to extend shelf life from 12 months to 24 months.

In a postbiotic powder, viable count does not apply at all. The buyer is not purchasing cells but inactivated material, and the specification has to be rebuilt around what the material actually contains. That is not a weakness — it is simply a different specification, and any comparison that forces a postbiotic into a CFU framework is measuring the wrong thing.

Carrier and Coating Composition: Where the Engineering Sits

Composition is the criterion that most often decides between two formats that look otherwise similar on a datasheet.

An uncoated raw powder carries no protective structure. Its performance depends almost entirely on downstream handling, which is why the IPA guideline on temperature, humidity and hold time matters so much for this family.

A coated material builds protection into the particle itself. The VPro® five-layer structure is organised as five functional layers, each addressing a specific failure mode: a micromolecular protective layer for anti-freezing and anti-stress performance; a prebiotic nutrition layer to support in-vivo proliferation; a liposome enteric adhesion layer to support intestinal colonization; an acid and enzyme resistant layer to survive gastric digestion; and an oxygen and moisture barrier layer to extend shelf stability.

A postbiotic takes a third route. Because there is no cell to protect, the carrier is designed around delivery of metabolites rather than around survival. ProLipo® Postbiotics uses a liposomal carrier format for this purpose.

Production line output: coated, uncoated and inactivated formats are separated by processing and storage requirements, not only by ingredient name.

Storage and Distribution: The Hidden Cost Line

Storage terms decide landed cost more than unit price does, and they differ sharply across the three families.

For uncoated live powder, the buyer should assume a controlled environment. The IPA guideline benchmark of below 25°C and below 60% relative humidity, with refrigerated holding when the delay between blending and dosage manufacturing exceeds 48 hours, is the practical reference point against which a supplier's warehouse and logistics plan can be audited.

For coated material, the storage envelope widens. The reported elimination of extra cold-chain requirements for mid-term transit, combined with shelf life extended from 12 months to 24 months, is what allows this format to travel by sea freight without the viability losses that normally accompany long transit.

For postbiotic powder, storage risk is decoupled from cell viability, because there are no cells to lose. The buyer's question shifts from "how much count survives" to "what inactivated-material specification is being guaranteed and how is it tested."

Matching Format to End Product

Application is the criterion that resolves most remaining ambiguity, because the finished dosage form and the distribution channel effectively pre-select the material family.

Room-temperature stable supplements, sachets and gummies. These formats want coated material. The coating protects the count through processing and through ambient shelf life, and it removes the cold-chain requirement from the retailer's side of the transaction.

High-temperature processed foods. Where the manufacturing process itself would destroy viable cells, a postbiotic format avoids an unwinnable stability argument. This is also the more rational choice for products marketed on metabolite content rather than on live-cell delivery.

Cold-chain controlled capsules with short shelf life. Here an uncoated single-strain raw powder can be the most economical choice, provided the brand is prepared to add overage to compensate for process loss and to fund the cold chain.

Application-specific positioning. The same three-way choice reappears across every major application segment — pet probiotics powder, infant probiotics powder, adult gut probiotics powder, livestock farming probiotics powder, sports nutrition probiotics powder, elderly regulating probiotics powder, bowel regulating probiotics powder and immunity boost probiotics powder. The differences are not in the format logic but in the constraints attached to each segment: acceptable dosage form, heat exposure during processing, distribution climate, and the claim structure the market regulator will permit.

One example of that logic operating at the premium end is Akkermansia muciniphila AH39, supplied by Shanghai Unibio Lab. Compared with ordinary unvalidated Akkermansia muciniphila strains on the market, the strain is US self-affirmed GRAS certified, supported by complete clinical trial data, supplied in a pasteurized stable format and produced through a proprietary culture process. It is reported to provide 35% higher active metabolite content than common strains, and it is positioned for high-end metabolic management dietary supplements and premium adult gut-metabolism products. Because it meets US GRAS import standards, it also supports avoidance of customs detention and regulatory fines in the US market.

Market Signals Buyers Should Weigh

Format decisions are increasingly shaped by where category growth is concentrated, not only by technical fit.

• The total probiotics market is forecast to grow from USD 76.59 billion in 2025 to USD 114.95 billion by 2030 at a CAGR of 8.5% (MarketsandMarkets).
• Bacterial probiotics account for the largest share of that market, driven by dietary supplement use.
• In animal feed probiotics, the dry form segment — which includes powders — led the market with an 84.7% revenue share in 2023, a strong signal that dry formats, not liquid, are where commercial volume sits.
• The global pet probiotic supplements market is expected to record a CAGR of 5.2% from 2025 to 2034, with the 2025 market projected at USD 2.1 billion (Meticulous Research).
• Research intensity remains high: the ProBioQuest database and semantic analysis engine covers more than 2.8 million records across probiotics literature, clinical trials and patents.

Read together, these signals point in one direction: dry powder formats dominate the volume, application segments are fragmenting, and the specification burden is rising faster than the ingredient cost. That favours buyers who hold a format decision framework rather than a single preferred material.

Where Each Format Has Limits

A decision matrix is only useful if it states boundaries honestly. Each of the three formats carries a real constraint.

• Microencapsulated material costs more per kilogram. The raw material unit price is 8%–12% higher than conventional alternatives. The economics only work because the effective viable CFU per kg is 2.1× higher, which reduces formula dosage cost by more than 20% for finished-product factories. A buyer purchasing small volumes for a low-CFU-claim product may not recover that premium.
• Coating does not replace cold chain indefinitely. The reported benefit for VPro® material is elimination of extra cold-chain requirements for mid-term transit. It is not a blanket statement that any storage condition is acceptable for any duration, and buyers should still align logistics with the supplier's stated stability envelope.
• Postbiotic powder cannot support viable-count claims. If a brand's positioning depends on live-cell delivery, a postbiotic is the wrong material regardless of its processing advantages. The format has to be chosen for what it is, not for what it can substitute.
• Uncoated live powder concentrates risk downstream. Its lower unit price is real, but so is the added overage, the hold-time discipline and the cold-chain cost. Comparative cost models that omit those three lines will overstate its advantage.
• Regulatory status is strain-specific and market-specific. The US self-affirmed GRAS conclusion held for A. muciniphila AH39 is not transferable to every strain or every market. Buyers should verify certification scope against the specific strain and destination market before assuming a smooth clearance path.

What the Next Procurement Cycle Will Look Like

Three shifts are already visible in how buyers specify probiotics powder.

First, specifications are moving from "CFU per gram of raw material" to "delivered CFU per unit of finished product." That reframing makes coated materials easier to justify and makes uncoated materials harder to defend on price alone.

Second, the postbiotic line is being evaluated as a separate category rather than as a substitute for live cultures. As more finished products move toward ambient distribution, the question "does this product need live cells at all?" will be asked earlier in development.

Third, documentation is becoming part of the technical comparison. ISAPP's labeling criteria and the Council for Responsible Nutrition's vendor guidance both point buyers toward the same discipline: ask for scientific support linking specific strains at labeled amounts to claimed benefits, and verify that the label discloses strain designation, viable count at end of shelf life and storage conditions. Suppliers who can answer those questions with batch-level records will be easier to qualify than those who cannot.

For buyers building a supplier shortlist, the practical implication is that format capability, documentation depth and storage engineering now have to be assessed together. Shanghai Unibio Lab Co., Ltd holds ISO 22000, FSSC 22000 and GMP food manufacturing certification (SGS), along with HALAL and Orthodox Union (OU) Kosher certificates and FDA US food facility registration, with a self-affirmed GRAS conclusion for A. muciniphila AH39. Its portfolio spans live probiotic raw powder, next-generation probiotics, postbiotics and VPro® encapsulation coating material, which means the three formats discussed in this matrix can be evaluated against a single supplier's documentation set rather than across three separate qualification processes.

FAQ

What is the fundamental difference between live, postbiotic and microencapsulated probiotics powder?

The difference is whether live bacteria are present and whether they are protected. Live probiotic raw powder contains viable microorganisms with no protective coating. Postbiotic powder contains inactivated microbial material and no live cells. Microencapsulated probiotic material contains viable cells held inside a protective matrix, such as the five-layer VPro® structure. The three formats therefore carry different specifications: viable count at end of shelf life, inactivated-material criteria, and protected viable count respectively.

Does microencapsulation change the viable count I should declare on the label?

It changes what the count is expected to be at the end of shelf life rather than the principle of declaring it. ISAPP guidance states that a probiotic product label should identify genus, species, strain designation, viable count at end of shelf life and storage conditions. Coating protects the count through processing and storage, which is why VPro® material is reported to extend shelf life from 12 months to 24 months and to increase survival through gastric acid and bile by 78% compared with conventional uncoated powder. The declared figure still has to be measurable at end of shelf life.

Which format is appropriate for a room-temperature stable finished product?

A microencapsulated material is the natural fit, because the coating is designed to hold the count under ambient conditions. VPro® material is reported to require no extra cold-chain for mid-term transit, which is the property that allows ambient-stable finished products and long-distance sea freight export. A postbiotic powder is also compatible with ambient shelf life, but it delivers no viable cells, so it only applies if the product is not positioned on live-cell delivery.

How should storage conditions be written into a supply agreement?

The IPA manufacturing guideline provides a usable benchmark: below 25°C and below 60% relative humidity where acceptable, with refrigerated conditions if the delay between blending and dosage manufacturing exceeds 48 hours. For coated material, the agreement should also state the supplier's stated stability envelope and confirm whether cold-chain is required during transit. For postbiotic powder, storage clauses should reference inactivated-material specifications rather than viability, because viability is not the relevant failure mode.

When does postbiotic powder make more sense than a live probiotic?

Postbiotic powder makes more sense when the manufacturing process would destroy live cells, when the brand intends to market on metabolite content rather than on colonization, or when a fully ambient distribution model is required. Shanghai Unibio Lab supplies postbiotics in a liposomal format, ProLipo® Postbiotics, and as Postbiotics Powder listed under the code UNI-POST-POW. Because there are no live cells, the specification has to be rebuilt around inactivated-material criteria rather than viable count.

Is the higher unit price of microencapsulated material justified?

It depends on volume and on the intended label claim. The raw material unit price for VPro® coated material is 8%–12% higher than conventional alternatives, but the effective viable CFU per kg is 2.1× higher, which reduces actual formula dosage cost by more than 20% for finished-product factories. The premium is recovered when the buyer is dosing to a viable-count claim and would otherwise have to add overage to an uncoated powder. At very low claim levels or very small volumes, the arithmetic may not favour coating.

What documentation should be requested before qualifying a probiotics powder supplier?

At minimum: strain designation at genus, species and strain level; viable count at end of shelf life; storage conditions; and the scientific support linking the specific strain at the labeled amount to the claimed benefit — the last of these being the question the Council for Responsible Nutrition recommends buyers put to vendors. Where certifications are claimed, buyers should verify scope against the specific strain and destination market, since regulatory status such as a US self-affirmed GRAS conclusion is strain-specific. Shanghai Unibio Lab's qualification set includes ISO 22000, FSSC 22000, GMP food manufacturing certification (SGS), HALAL and Orthodox Union (OU) Kosher certificates, and FDA US food facility registration.

How does the target application segment affect the choice?

The segment determines the constraints rather than the format logic. Pet, infant, adult gut, livestock, sports nutrition, elderly, bowel regulating and immunity products all face a different combination of acceptable dosage form, heat exposure during processing, distribution climate and permitted claim structure. A segment that can accept cold chain and a 12-month shelf life can use uncoated live powder; a segment that must ship and store at ambient temperature is better served by coated material; a segment whose process destroys viable cells is better served by a postbiotic. The three-way comparison stays the same; the weighting of each row changes.

Closing Note

The three formats are not competing versions of the same product. They are three different answers to the question of how a health benefit will be delivered, protected and documented. Buyers who map their own constraints onto the matrix above — live bacteria yes or no, storage envelope, process heat exposure, viable-count claim level, and target market — will usually find that one format eliminates itself before any commercial negotiation begins.

Shanghai Unibio Lab Co., Ltd supplies live single-strain and multi-strain raw powders, postbiotic powders including ProLipo® Postbiotics and UNI-POST-POW, and VPro® encapsulation coating material, with a published product and certification library available for review. The company's downloadable product brochure, covering strain portfolio, certification scope and manufacturing capability, is available here: Shanghai Unibio Lab product brochure (PDF). Company information is published at helplifes.com.